CJC-1295 (no DAC)
CJC-1295 (no DAC), also called Modified GRF (1-29), is a short-acting synthetic GHRH analog studied for stimulating pulsatile GH and IGF-1 release; research protocols typically use around 100 mcg subcutaneously, often twice daily.
Best for
It has been studied in research settings as a GHRH analog for stimulating pulsatile endogenous growth hormone and IGF-1 secretion, with interest in muscle, fat metabolism, and recovery contexts.
What to expect
Research describes a rapid, short-lived GH pulse following subcutaneous administration, with the compound's brief plasma presence producing an acute response rather than sustained elevation.
Pairs with
It is most commonly studied stacked with a growth hormone secretagogue such as Ipamorelin, which acts on a complementary pathway to amplify the GH pulse.
In research literature the no-DAC form is typically described as administered subcutaneously, often in microgram-scale doses given one or more times daily (frequently around or before sleep), reflecting its short duration and pulsatile profile.
- How often
- Daily · 2×/day
- When
- Bedtime · Post-workout
- Route
- Subcutaneous
- Vial & water
- 10 mg vial in 3 mL = 3.33 mg/mL · 100 mcg = 3 units on a U-100 syringe
- Cycle
- Continuous
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
CJC-1295 (no DAC) — also known as Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH), corresponding to the first 29 residues of native GHRH.
CJC-1295 is not FDA-approved; the parent compound was an investigational drug abandoned after early-phase trials and it is used today as a research compound only.
It carries four amino acid substitutions (positions 2, 8, 15, and 27) engineered to resist enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), extending its functional life beyond that of native GHRH while preserving receptor binding. Research characterizes it as acting on GHRH receptors on somatotroph cells of the anterior pituitary, where it has been studied for stimulating endogenous growth hormone (GH) release in a pulsatile pattern that more closely mimics natural secretion.
Unlike the DAC-conjugated version (which binds albumin for a multi-day half-life), the no-DAC form is short-acting.
- Half-life
- ~30 min plasma (short-acting; no-DAC form)
- Peak
- ~15-30 min post-SC GH pulse (reported)
- Absorption
- Subcutaneous; rapid uptake
- Bioavailability
- Not well characterized in published human PK for the no-DAC form
References3
- Soule S et al. - Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men (J Clin Endocrinol Metab)
- Teichman SL et al. - Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (J Clin Endocrinol Metab)
- Ionescu M, Frohman LA - Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (J Clin Endocrinol Metab)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.